TNYA

Tenaya Therapeutics, Inc.

• Benzinga·03/24 12:05

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• Simply Wall St·03/14 01:36

  How TN-301 Progress And Alnylam Deal At Tenaya Therapeutics (TNYA) Has Changed Its Investment Story

• Simply Wall St·03/12 20:18

  Tenaya Therapeutics (TNYA) Valuation After TN-301 Data And New Alnylam Collaboration

• TipRanks·03/12 17:10

  Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Sagimet Biosciences, Inc. Class A (SGMT)

• TipRanks·03/12 14:35

  Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics

• Dow Jones·03/12 12:38

  Tenaya Therapeutics Price Target Maintained With a $8.00/Share by Chardan Capital

• Dow Jones·03/12 12:38

  Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

• TipRanks·03/12 12:15

  Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target

• TipRanks·03/12 11:35

  Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating

• Reuters·03/11 20:37

  Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027

• TipRanks·03/11 20:27

  Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)

• Benzinga·03/11 20:10

  Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate

• Reuters·03/11 20:08

  Tenaya Therapeutics Q4 net loss narrows 15% to USD 20.18 million

• Dow Jones·03/11 20:07

  *Tenaya Therapeutics Sees Extending Cash Runway Into 2H of 2027 >TNYA

• Reuters·03/11 20:05

  BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million